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Recently I left the University of Southern California (USC)
School of Medicine in Los Angeles. Many projects relating to
oocyte donation were initiated during my 8 years there, and a
great deal was accomplished to change the way most of us
now view ageing and reproduction. Over the years I have
frequently been asked to help set up programmes or review
the ongoing progress of centres involved in oocyte donation.
Accordingly, one might think it relatively easy to move sites
and begin anew. However, as I began to reorganize the
programme at Columbia University in New York, I found
myself facing serious controversies that have altered the
public's perception of this technique. Indeed, the entire field
of reproductive medicine has recently come under fiery criti-
cism over issues involving gamete donation. The news media
appear to be fanning the flames knowing that a distrusting
public has realized its worst nightmare. Unfortunately, many
of these criticisms are justified.
When I arrived at USC in 1987, most members of our
department were sceptical that oocyte and embryo donation
would ever play a significant role in assisted reproduction.
Certainly, outside of research circles there was little demand
for the service. Previously, while working at Harbor-UCLA I
had witnessed years of debate regarding the ethics of embryo
donation. The payment for services, anonymity of participants,
and the rather unconventional arrangement inherent to the
method were debated then as they are today. Many of these
concerns puzzled me since men had provided similar services
without evoking fear or criticism. The double standard was
obviously sexist, yet could not be dismissed. To appease critics
certain 'safeguards' were invoked to address the myriad of
newly identified concerns. Psychologists were introduced into
the formal screening process of donors and recipients. Lawyers
and hospital administrators were consulted over policies gov-
erning employment and insurance to protect against injury,
disability or death. Many of these practices have remained
standard features of programmes. As a result, oocyte donation
has grown to become complicated and expensive, partly due
to the addition of outside consultants. Duties once assumed
by primary physicians are now commonly subcontracted or
delegated to others.
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In the early days, emphasis was placed on the recruitment
of 'fertile' women as donors. Today in the USA, groups openly
advertise and aggressively solicit young women to participate.
A decade ago the idea of unmarried, nulliparous women,
typically still in school, undergoing an invasive procedure as
part of a study protocol was unthinkable. This proposal would
have undoubtedly been rejected by the institutional review
board (IRB) as unreasonable since the risks of ovarian hyper-
stimulation and follicle aspiration far outweighed any benefit
to the patient-donor. So what's different today? Labelling the
practice 'standard' or 'conventional' seems to have justified
it Unfortunately, it appears the obligations of 'standard prac-
tice' are less rigorous than those imposed upon the same
subjects undertaking peer-reviewed clinical trials. More than
2500 cases of oocyte donation are currently performed annually
in the USA and issues of supply and demand have become
paramount. There do not appear to" be enough fertile young
mothers available to meet the public's need. But there has
arisen a demand for younger female students which seems to
be generated by- more selfish interests.
The demographic character of recipients has also changed.
Originally most women I evaluated were similar to those in
the general pool of infertile patients. The first reports of oocyte
and embryo donation principally involved young women with
tubal disease wishing to avoid surgical attempts at oocyte
retrieval. By the mid-1980s, the method was offered to
functionally agonadal patients. This dramatically altered the
focus of care. Patients with premature ovarian failure and
individuals with genetically inheritable disease states, were
followed by peri-menopausal and menopausal women seeking
services. The right to access reproductive care became a real
issue. Should assisted reproduction be used to treat single
older women and lesbians? How do we prospectively test for
the ability to parent? What standards for parenting apply to
these new groups of patients? Presently, there appear to be a
lot more questions than answers.
Debate over limiting oocyte donation to younger recipients
continues. There are concerns over the health of the older
mother and her fetus during pregnancy. There is worry as to
whether older women have the stamina to raise a child to
adulthood. In the USA the practice of oocyte donation has
been essentially unrestricted except for constraints imposed
by individual physicians. However, elsewhere in the world
laws have been passed to limit care. Again, are these concerns
justified by the clinical work reported to date, or is this another
unfair prejudice?
Costs continue to escalate; 10 years ago donors received
$250 per cycle. Today $2500 is not uncommon. Is a 10-
fold increase really merited? Again, I doubt the IRB would
have approved such an enormous fee in 1984. What is






















this level are more easily justified as business expenditures
than reimbursements to human subjects for time spent in a
clinical trial. If inflated compensation justifies exaggerated
risk then perhaps no one should participate. A $2500 payment
may certainly be considered an enticement, especially when
offered to students.
While attending the World Congress of in-vitro fertilization
(IVF) in Vienna I was impressed by the almost unanimous
criticism levelled at practitioners in the USA by colleagues
abroad with respect to the payment of donors. Allegations of
'pimping* for patients in need of eggs seemed a rather cruel
accusation at the time, and yet as donors' fees continue to rise
I am increasingly reminded of the obvious shift away from
altruism. Yet, one cannot blame the donors when advertise-
ments read 'We pay top dollar' as recently advertised in
Los Angeles.
I don't believe any of us expected oocyte donation to
establish itself so quickly nor did we anticipate how well
it would ultimately work. Life-table analysis of 500
consecutive cycles performed at USC demonstrates live
births in >50% of the women by the third consecutive
cycle and >90% by the fifth try. Although five cycles of
oocyte donation is fiscally draining, few if any fertility
treatments come close to matching these statistics. Donor
oocytes add an unexpected element of success into situations
traditionally viewed as grim. This infusion of hope is
inherently uplifting and a welcome addition to most
programmes where failure is more commonly the norm.
If I sound somewhat pessimistic and dismayed at the state
of things today it is because I am. We have accomplished so
many great things in so short a time. I am afraid that
these accomplishments may soon be overshadowed by the
increasingly questionable practices taking hold of oocyte
donation. Lest it become like surrogacy, unaffordable to most,
and fraught with legal entanglements, it is time to guard
against moneyed and special interests profiting from the
desperation of our patients and exploiting the goodwill of most
donors. We should be vigilant in protecting against tasteless
advertisements and questionable business practices. I would
like to believe that strong condemnation by professional peers
may still have some impact. I have always believed it best for
physicians to choose the way in which they wish to practice
medicine. After all, that is what defines us as professionals.
However, it is also up to us to police ourselves and our
practices unless we wish to forfeit this right.
Problems with oocyte donation
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The rather pessimistic paper by Sauer (1996) leads me to
a few comments. Firstly, new advances in medical science
happen in a rectilinear and univocal manner. There are
always excesses, interdicts and contradictions which, over
time, would make one believe that the image of progress
is altered or misled.
It is also possible to consider that oocyte donation does
not represent either social or medical progress. If so, then
sperm and embryo donation should also be condemned. I,
for one, cannot accept such arguments. If oocyte donation
allows women who are totally infertile to bear the child
they and their partners so much long for, we should express
our satisfaction that medically-assisted procreation has
permitted this, and search for the most constructive ways
to carry it out.
Secondly, the problem of money is a very important one. I
know little about the situation in the USA, but in France,
any gratuity paid for gamete and embryo donation must be
comparable with that paid for organ donation. Nevertheless,
the principle of payment for expenses incurred by the donors
for conservation and preservation is accepted; this is also the
case for sperm donation. We have always considered that our
American colleagues should tend to act towards gratuity; the
American Society for Reproductive Medicine (ASRM) advises
them to do so. The number of donors will surely diminish
and, as a consequence, questions will arise about the problem
of donor anonymity. These questions are all being discussed
worldwide and solutions to them are likely be drawn into an
international consensus in a few years. They should not alter
our confidence in the fundamental aim of our work which is
to give a child to infertile women.
Thirdly, the problem of the indications for donation must
also be discussed. While there is apparently widespread agree-
ment for using it for infertile women, its role for premature
menopause, risk of transmission of a genetic disease, and the
maximum age at which donation can apply is still under
discussion. Maybe the choice should be guided by the well-
being of the child to be born. If decisions were taken on the
basis of the child's welfare and not only the desire of the
parents to conceive, many cases apparently shocking in current
practice would become humanly acceptable. This progression
seems to happen gradually throughout the world and excep-
tional cases only remain as anecdotal cases.
To sum up, I agree in the main with Professor Sauer's
criticisms, although I differ in my vision of the future. I
am more optimistic about medically-assisted procreation in
general, and oocyte donation in particular, which allows
couples to have the child they long for and for a desired and
happy child to be born. Criticism is necessary, for these
procedures can influence choices of behaviour in the recipients.
International debates allow each country to compare its
methods with others. As each day passes, the shocking aspects
of donation will disappear little by little, and what will remain
will be the great happiness of couples bearing the child they
wish for when Nature has apparently forbidden it.
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